severe allergic asthma
Respiratory · 2009–2016
5decisions
1medicine
3carried consumer input
5individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| omalizumab Treatment of severe allergic asthma in patients aged 6 to less than 12 years who have failed to achieve adequate control despite optimised asthma therapy. | Jul 2016 | Recommended with restriction | input received |
| omalizumab Amendment to PBS eligibility criteria for severe allergic asthma to allow patients with baseline IgE 30-75 IU/mL (in addition to the current IgE ≥76 IU/mL… | Nov 2015 | Recommended with restriction | input received |
| omalizumab Treatment of patients aged 12 years or older with uncontrolled severe allergic asthma who have failed to achieve adequate control with optimised asthma therapy. | Nov 2014 | Recommended with restriction | 5 individuals |
| omalizumab Initial and continuing treatment of patients with uncontrolled severe allergic asthma, aged 12 years or older, who meet specific clinical criteria including… | Nov 2010 | Not recommended | no section in document |
| omalizumab Initial and continuing treatment of patients with uncontrolled severe allergic asthma, aged 12 years or older, who have failed to achieve adequate control with… | Nov 2009 | Recommended with restriction | no section in document |
What the PBS pays
$51M in government benefit over 2024–25, across 82,658 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| omalizumab | $50.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.